MA52813A - Inhibiteurs de sarm1 - Google Patents
Inhibiteurs de sarm1Info
- Publication number
- MA52813A MA52813A MA052813A MA52813A MA52813A MA 52813 A MA52813 A MA 52813A MA 052813 A MA052813 A MA 052813A MA 52813 A MA52813 A MA 52813A MA 52813 A MA52813 A MA 52813A
- Authority
- MA
- Morocco
- Prior art keywords
- sarm1 inhibitors
- sarm1
- inhibitors
- Prior art date
Links
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 title 1
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682033P | 2018-06-07 | 2018-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52813A true MA52813A (fr) | 2021-04-14 |
Family
ID=68769462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052813A MA52813A (fr) | 2018-06-07 | 2019-06-06 | Inhibiteurs de sarm1 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12338238B2 (fr) |
| EP (1) | EP3801500B1 (fr) |
| JP (2) | JP2021527125A (fr) |
| CN (1) | CN112839647B (fr) |
| CA (1) | CA3102645A1 (fr) |
| ES (1) | ES3028093T3 (fr) |
| MA (1) | MA52813A (fr) |
| WO (1) | WO2019236879A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3801503A4 (fr) | 2018-06-07 | 2021-12-08 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 |
| US12448374B2 (en) | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| MA52813A (fr) | 2018-06-07 | 2021-04-14 | Disarm Therapeutics Inc | Inhibiteurs de sarm1 |
| CN113164508B (zh) | 2018-12-19 | 2025-07-08 | 达萨玛治疗公司 | 与神经保护剂组合的sarm1抑制剂 |
| US12624025B2 (en) | 2019-06-06 | 2026-05-12 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| WO2020252229A2 (fr) | 2019-06-14 | 2020-12-17 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 |
| US12441719B2 (en) | 2019-09-12 | 2025-10-14 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| AU2020391206A1 (en) * | 2019-11-26 | 2022-05-19 | Disarm Therapeutics, Inc. | Methods and compositions for neuroprotection |
| WO2021207302A1 (fr) * | 2020-04-09 | 2021-10-14 | Disarm Therapeutics, Inc. | Dérivés d'indazole utiles en tant qu'inhibiteurs de sarm1 |
| EP4132928B1 (fr) * | 2020-04-09 | 2025-12-24 | Disarm Therapeutics, Inc. | Dérivés de pyrazole condensés comme inhibiteurs de sarm1 |
| US20230287428A1 (en) * | 2020-05-27 | 2023-09-14 | Emendobio Inc. | Biallelic knockout of sarm1 |
| TWI904906B (zh) | 2020-08-24 | 2025-11-11 | 美商達薩瑪治療公司 | Sarm1之抑制劑 |
| US20250361234A1 (en) * | 2022-06-06 | 2025-11-27 | Nico Therapeutics, Inc. | Compounds, compositions, and methods |
| JP2025520511A (ja) * | 2022-06-17 | 2025-07-03 | ニューロン２３， インコーポレイテッド | キナーゼモジュレーターおよびその使用方法 |
| EP4655295A1 (fr) | 2023-01-24 | 2025-12-03 | Disarm Therapeutics, Inc. | 1h-pyrazole-4-carboxamides substitués en tant qu'inhibiteurs de sarm1 |
| TW202509019A (zh) * | 2023-04-27 | 2025-03-01 | 香港商維泰瑞隆（香港）生物科技有限公司 | Sarm1調節子、其製劑及用途 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1022214A (en) | 1963-01-31 | 1966-03-09 | Sterling Drug Inc | Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation |
| US3506668A (en) | 1965-01-26 | 1970-04-14 | Sterling Drug Inc | Method of preparing 8-hydroxy-quinolines |
| US3429887A (en) | 1965-01-26 | 1969-02-25 | Sterling Drug Inc | 1,7-naphthyridine-3-carboxylic acid derivatives and their preparation |
| US3429882A (en) | 1968-03-25 | 1969-02-25 | Geigy Chem Corp | 1,2,8,9-tetraazaphenalenes |
| US3761493A (en) | 1968-04-23 | 1973-09-25 | Ciba Geigy Corp | 3-dibromomethylphthalic anhydride |
| US3539567A (en) | 1968-04-23 | 1970-11-10 | Geigy Chem Corp | 8-carboxy-1(2h) phthalazinones |
| US3624108A (en) | 1968-04-23 | 1971-11-30 | Geigy Chem Corp | 7-carboxyphthalides |
| US3629251A (en) | 1968-08-12 | 1971-12-21 | Geigy Chem Corp | Derivatives of 9-aminoalkyl-1 2 8 9-tetraazaphenalenes |
| US3517014A (en) | 1969-06-16 | 1970-06-23 | Sterling Drug Inc | Method of preparing 8-hydroxyquinoline-3-carboxylic acids |
| US3711473A (en) | 1970-04-06 | 1973-01-16 | Ciba Geigy Corp | 3-hydrazino-1,2,8,9-tetraazaphenalenes |
| CA1043616A (fr) | 1973-10-16 | 1978-12-05 | Fuji Photo Film Co. | Materiau photosensible a developpement thermique |
| US4207112A (en) | 1974-01-29 | 1980-06-10 | Fuji Photo Film Co., Ltd. | Heat developable light-sensitive materials |
| JPS50123331A (fr) | 1974-03-14 | 1975-09-27 | ||
| GB9310700D0 (en) * | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Novel composition |
| AU2001259218A1 (en) | 2000-04-27 | 2001-11-07 | Abbott Laboratories | Substituted phenyl farnesyltransferase inhibitors |
| CA2707827A1 (fr) | 2001-04-11 | 2002-10-24 | Senju Pharmaceutical Co., Ltd. | Agents servant a ameliorer la fonction visuelle contenant des inhibiteurs de la rho kinase |
| ES2211344B1 (es) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| WO2005102345A1 (fr) * | 2004-03-30 | 2005-11-03 | Alcon, Inc. | Utilisation d'inhibiteurs de kinase rho dans le traitement de deficits auditifs, d'acouphenes et dans l'amelioration de l'equilibre corporel |
| US20060078890A1 (en) * | 2004-10-08 | 2006-04-13 | Ole Isacson | Methods for identifying parkinson's disease therapeutics |
| EP1899322B1 (fr) * | 2005-06-28 | 2009-09-02 | Sanofi-Aventis | Derives d'isoquinoline utilises en tant qu'inhibiteurs de rhokinase |
| SI1912949T1 (sl) * | 2005-07-26 | 2011-12-30 | Sanofi Sa | Cikloheksilamin izokinolonski derivati kot inhibitorji Rho-kinaze |
| CN101277939A (zh) | 2005-09-09 | 2008-10-01 | 布里斯托尔-迈尔斯斯奎布公司 | 无环ikur抑制剂 |
| GB0605766D0 (en) | 2006-03-22 | 2006-05-03 | Ucb Sa | Process |
| US20100004244A1 (en) | 2006-06-27 | 2010-01-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of cb2 receptor agonists for promoting neurogenesis |
| KR20090029261A (ko) | 2006-07-13 | 2009-03-20 | 노파르티스 아게 | 신경계 장애의 치료에서의 트리플루오로메틸-치환 벤즈아미드의 용도 |
| JP5599783B2 (ja) * | 2008-05-30 | 2014-10-01 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| JP2010053073A (ja) * | 2008-08-28 | 2010-03-11 | Sankyo Kasei Kk | ハロゲン化イソキノリン類の製造方法 |
| US8450363B2 (en) * | 2009-02-06 | 2013-05-28 | Elan Pharmaceuticals, Inc. | Inhibitors of Jun N-terminal kinase |
| US9249087B2 (en) * | 2011-02-01 | 2016-02-02 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
| DE102011009961A1 (de) | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| WO2012178022A2 (fr) | 2011-06-24 | 2012-12-27 | University Of Massachusetts | Applications thérapeutiques ciblant sarm1 |
| WO2013005157A1 (fr) * | 2011-07-05 | 2013-01-10 | Lupin Limited | Dérivés de sulfone et leur utilisation en tant que modulateurs de pkm2 pour le traitement du cancer |
| DE102012019369A1 (de) * | 2012-10-02 | 2014-04-03 | Merck Patent Gmbh | 7-Azaindolderivat |
| CA2916557C (fr) | 2013-06-24 | 2021-08-03 | Merck Patent Gmbh | Derives de phtalazine |
| WO2015050471A1 (fr) * | 2013-10-02 | 2015-04-09 | Obschestvo S Ogranichennoy Otvetstvennost'yu "Panacela Labs" | Composés carbazole et leurs méthodes d'utilisation |
| WO2015102929A1 (fr) * | 2013-12-30 | 2015-07-09 | Novartis Ag | Dérivés de sulfonamide tricycliques |
| FR3017868A1 (fr) | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP6581111B2 (ja) * | 2014-04-28 | 2019-09-25 | メッドシャイン ディスカバリー インコーポレイテッド | Ｒｈｏキナーゼ阻害剤としてのイソキノリンスルホン誘導体 |
| US9877957B2 (en) * | 2014-09-05 | 2018-01-30 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
| CA3011189C (fr) | 2016-01-14 | 2024-02-20 | Bayer Pharma Aktiengesellschaft | 2-(morpholin-4-yl)-1,7-naphthyridines substituees en 5 |
| WO2018035204A1 (fr) | 2016-08-16 | 2018-02-22 | Henry Ford Health System | Compositions pour le traitement de la douleur neuropathique et la sensibilisation des tumeurs aux chimiothérapies |
| WO2018057989A1 (fr) | 2016-09-24 | 2018-03-29 | Washington University | Inhibiteurs de l'activité sarm1 nadase et utilisations de ceux-ci |
| EP3596051B1 (fr) * | 2017-03-13 | 2022-04-27 | Impetis Biosciences Ltd. | Composés bicycliques fusionnés, compositions et applications correspondantes |
| US12448374B2 (en) | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| MA52813A (fr) | 2018-06-07 | 2021-04-14 | Disarm Therapeutics Inc | Inhibiteurs de sarm1 |
| EP3801503A4 (fr) | 2018-06-07 | 2021-12-08 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 |
| CN109293635A (zh) | 2018-10-04 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型btk激酶抑制剂的p晶型及其制备方法 |
| CN109223787A (zh) | 2018-10-04 | 2019-01-18 | 南京先进生物材料与过程装备研究院有限公司 | 一种喜树碱和新型酞嗪酮类化合物联合用药物组合物 |
| CN109180642A (zh) | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 酞嗪酮类btk抑制剂及其应用 |
| CN109485636A (zh) | 2018-10-04 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型btk激酶抑制剂的盐酸盐及其制备方法与用途 |
| CN109336863A (zh) | 2018-10-04 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型酞嗪酮类btk抑制剂、制备及其应用 |
| CN112955150A (zh) * | 2018-10-19 | 2021-06-11 | 达萨玛治疗公司 | 与nad+或nad+前体组合的sarm1抑制剂 |
| CN109481441A (zh) | 2018-10-31 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和新型甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用 |
| CN109172562A (zh) | 2018-10-31 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用 |
| CN109394766A (zh) | 2018-10-31 | 2019-03-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和对苯硝基酞嗪酮类btk抑制剂联合用药物组合物及其应用 |
| CN109276571A (zh) | 2018-10-31 | 2019-01-29 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和新型硝基酞嗪酮btk抑制剂联合用药物组合物及其应用 |
| CN109331018A (zh) | 2018-10-31 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和硝基酞嗪酮btk抑制剂联合用药物组合物及其应用 |
| EP4174170A4 (fr) | 2020-06-25 | 2023-12-06 | FUJIFILM Corporation | Procédé de production de cellules épithéliales intestinales et leur utilisation |
-
2019
- 2019-06-06 MA MA052813A patent/MA52813A/fr unknown
- 2019-06-06 ES ES19816172T patent/ES3028093T3/es active Active
- 2019-06-06 CN CN201980052437.0A patent/CN112839647B/zh active Active
- 2019-06-06 WO PCT/US2019/035833 patent/WO2019236879A1/fr not_active Ceased
- 2019-06-06 US US16/972,684 patent/US12338238B2/en active Active
- 2019-06-06 EP EP19816172.1A patent/EP3801500B1/fr active Active
- 2019-06-06 CA CA3102645A patent/CA3102645A1/fr active Pending
- 2019-06-06 JP JP2021518045A patent/JP2021527125A/ja active Pending
-
2023
- 2023-11-30 JP JP2023203259A patent/JP7576145B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7576145B2 (ja) | 2024-10-30 |
| CN112839647A (zh) | 2021-05-25 |
| WO2019236879A1 (fr) | 2019-12-12 |
| US12338238B2 (en) | 2025-06-24 |
| ES3028093T3 (en) | 2025-06-18 |
| EP3801500B1 (fr) | 2025-03-05 |
| US20210261540A1 (en) | 2021-08-26 |
| CN112839647B (zh) | 2025-09-23 |
| JP2021527125A (ja) | 2021-10-11 |
| EP3801500A4 (fr) | 2022-03-02 |
| JP2024037770A (ja) | 2024-03-19 |
| EP3801500A1 (fr) | 2021-04-14 |
| CA3102645A1 (fr) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| EP4007752C0 (fr) | Inhibiteurs de kif18a | |
| EP4007753C0 (fr) | Inhibiteurs de kif18a | |
| MA52812A (fr) | Inhibiteurs de sarm1 | |
| EP4007756C0 (fr) | Inhibiteurs de kif18a | |
| IL269196A (en) | Novel inhibitors | |
| EP3843714A4 (fr) | Inhibiteurs de cd73 | |
| EP3833355A4 (fr) | Inhibiteurs de prmt5 | |
| DK3740479T3 (da) | Dna-pk-hæmmere | |
| EP3788042A4 (fr) | Inhibiteurs de bcl-2 | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| EP3801499A4 (fr) | Inhibiteurs de sarm1 | |
| EP3541932A4 (fr) | Inhibiteurs de crispr-cas9 | |
| MA52635A (fr) | Inhibiteurs de magl | |
| EP3980011C0 (fr) | Inhibiteurs de sarm1 | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| EP3856176A4 (fr) | Inhibiteurs de vap-1 | |
| EP3787635A4 (fr) | Inhibiteurs de cd73 | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| EP3773537A4 (fr) | Inhibiteurs de stat3 | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| EP3856194A4 (fr) | Inhibiteurs de vap-1 | |
| MA51611A (fr) | Inhibiteurs de pi4kiiibêta |